Homepage Top Section1

As per the agreement, Sanofi will manufacture 125 million doses of the Covid-19 vaccine in Europe. Initial supplies of vaccine are expected to come out of Sanofi’s facilities

BIO 300 is Humanetics’ drug candidate which is expected to counteract and relieve not only severe and chronic inflammatory diseases but also radiation toxicities. The progressive pulmonary inflammation

As part of the development, Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have signed an agreement to

Under the deal, the US-based biotech company has granted an exclusive, worldwide, royalty-bearing license to Takeda Pharmaceutical pertaining to cell and non-cell therapy products that modulate targets identified

According to the India-based pharma company, the Sputnik V vaccine has been recommended by an independent data and safety monitoring board (DSMB) to advance to a phase 3

The in vitro study, which was held by Pfizer and the University of Texas Medical Branch (UTMB), demonstrated that the antibodies from people subjected to the vaccine could

The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients

The conditional marketing authorisation is based on the recommendation of the European Medicines Agency (EMA) for use of the Covid-19 Vaccine Moderna for active immunisation to prevent Covid-19

Under the deal, LakePharma will produce Akston’s adjuvanted Covid-19 vaccine candidate (AKS-452), which is slated to start phase 1/2 clinical testing later this month. LakePharma president and CEO